MSD And CKD In Multi-Product Korea Partnership To Boost Sales
This article was originally published in PharmAsia News
Chong Kun Dang Pharmaceutical has tied up with MSD Korea to beef up its diabetes and hyperlipidemia portfolios, in a move that could also help the US firm benefit from the South Korean pharma's leading position in the domestic cardiovascular market.
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR - How To Survive Changing And Confusing Times
May 26 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.